| ●Editorial | Shimizu N | 4-6 |
| ●Clinical trial registration and the issue of "Mixed health insurance" | ||
| ・Clinical trial registration: On the statement by ICMJE | ||
| Making clinical trial results public within the pharmaceutical regulatory and administrative frameworks in Japan | Mori K | 7-13 |
| On the registration of clinical trials and trial results disclosure | Uwoi T | 15-24 |
| Clinical trial registration and reporting─A provider's perspective─ | Sase K, Doi K, Kada A | 25-36 |
| Clinical trials unnecessary：Reflections on the contraindication of SSRIs in children and adolescents | Saio T | 37-44 |
| Clinical trial information as public goods Situations in Japan, the United States, and the European Union | Fukushima M, Kurihara C, Mitsuishi T | 45-64 |
| Full disclosure of evidence in published papers to prevent drug disasters ─Lessons from citizens' pharmacovigilance activities─ | Hama R | 65-98 |
| Clinical trials for patients─From the experiences of IDEA FOUR | Asano Y | 99-104 |
| Clinical trials：A crossroads of patients and drug disaster victims' perspectives | Hanai J | 105-9 |
| The Vancouver group: from reference style to publication ethics | Yamazaki S | 111-3 |
| Trial registration and medical journalism | Iwaishi T | 115-6 |
| Round table discussion：The impact of the ICMJE policy on clinical trial registration | Rinsho Hyoka Editorial Committee | 117-36 |
| ・"Mixed health insurance" and unauthorized drug use | ||
| Round table discussion：What is the future of unauthorized drug use in Japan? Reform of the insurance system and clinical trials | Sekino H, Ueda K, Kurihara M, et al. | 149-212 |
| ●Original | ||
| Individual consumption of Mifepristone (RU486) as an oral abortion pill | Matsumoto K, Saotome T | 213-31 |
| Problems in clinical activities by medical students： Political institutionalization of non-licensed medical practices for education and training purposes | Inoue Y | 233-57 |
| Survey of the attitude of physicians, patients and clinical research coordinator on clinical trials | Fukunaga T, Ikeda H, Tsukamoto H, et al. | 259-70 |
| ●Material | ||
| Review：2004 Revision of the French Human Research Participants Protection Act | Nudeshima J | 271-84 |
| Code de la Santé Publique Premiére Parti, Livre Ier Titre Ⅱ. Recherches biomédicales | （trans. by Nudeshima J） | 285-95 |
| "Number needed to screen" as an application of the F method: understanding diverse indicators derived from "number needed to treat" |
Saio T, Fujita T | 297-9 |
| Number needed to screen：development of a statistic for disease screening | Rembold CM （trans. by Saio T, Fujita T） | 301-10 |
| FDA Pharmacogenomics Guidance：Impact on drug development | Ronald A. Salerno （trans. by Azuma J, Katoh K） | 311-22 |
| ●Forum | ||
| Beta-lactam antibiotics: Do they prevent neuro-degeneration? | Nakajima A | 323 |
| Price of drugs | Nakajima A | 323-4 |
| The MHLW meeting on gefitinib, January 20, 2005 - A private view | Hiroshima A | 324-7 |
| ●Yorio Sato (1923-2005) | Kurihara M | 329-30 |
| ●Instructions for authors [English] | 331-6 | |
| ●Editor's note | Ohashi K | 337 |